

2020年度 業績

「英文論文」

1. Yamamoto Y, Otori T, Inoue R, Yano S, Hirata H, Matsumoto H, Matsuyama K, Matsuyama H. Pharmacokinetics of Neoadjuvant Axitinib Influenced the Efficacy in Patients With Advanced Renal Cell Carcinoma. *J Clin Pharmacol*. 2020 Feb;60(2):256-263. doi: 10.1002/jcph.1521.
2. Yamamoto Y, Matsuyama H, Matsumoto H, Sakano S, Fuji N, Oba K, Yamamoto M, Kamiryo Y, Hiragino T, Nagao K, Takai K, Aoki A. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma. *Jpn J Clin Oncol*. 2020 Feb 17;50(2):214-220. doi: 10.1093/jjco/hyz168.PMID: 31755525
3. Nakayama Y, Isoyama N, Yamamoto T, Nagata Y, Matsumura M, Fujikawa K, Matsuyama H, Shiraishi K. Receptor activator of the NFκB ligand system protects renal function during experimental renal ischemia-reperfusion in mice. *Transpl Immunol*. 2020 Feb;58:101263. doi: 10.1016/j.trim.2020.101263.
4. Shiota M, Fujimoto N, Yamamoto Y, Takeuchi A, Tatsugami K, Uchiumi T, Matsuyama H, Eto M. Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer. *Cancer Immunol Immunother*. 2020 Jul;69(7):1155-1163.
5. Ikeda A, Kojima T, Kawai K, Hinotsu S, Keino N, Shiga K, Miyake H, Miyata Y, Enomoto Y, Shimizu F, Anai S, Matsuyama H, Suzuki C, Kanimoto Y, Shigeta K, Naito S, Akaza H, Nishiyama H. Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow-up study in Japan. *Int J Clin Oncol*. 2020 Jun;25(6):1163-1169. doi: 10.1007/s10147-020-01634-9.
6. Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H. Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper. *Int J Urol*. 2020 Mar 14. doi: 10.1111/iju.14210
7. Matsubara N, Suzuki K, Kazama H, Tsukube S, Seto T, Matsuyama H. Cabazitaxel in patients aged ≥ 80 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan. *J Geriatr Oncol*. 2020 Mar 17. pii:

- S1879-4068(19)30502-8. doi: 10.1016/j.jgo.2020.02.014.
8. Nakamura K, Nagata Y, Hiroyoshi T, Isoyama N, Fujikawa K, Miura Y, Matsuyama H, Kuro-O M. The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients. The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients. *Clin Exp Nephrol.* 2020 Apr;24(4):323-329. doi: 10.1007/s10157-019-01832-4.
 9. Shiraishi K, Tabara M, Matsuyama H. Transcriptome Analysis to Identify Human Spermatogonial Cells from Sertoli Cell-Only Testes. *J Urol.* 2020 Apr;203(4):809-816. doi: 10.1097/JU.0000000000000682.
 10. Tomita Y, Naito S, Sassa N, Takahashi A, Kondo T, Koie T, Obara W, Kobayashi Y, Teishima J, Takahashi M, Matsuyama H, Ueda T, Yamaguchi K, Kishida T, Shiroki R, Saika T, Shinohara N, Oya M, Kanayama HO. Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC. *Clin Genitourin Cancer.* 2020 Mar 6:S1558-7673(19)30016-3. doi: 10.1016/j.clgc.2020.01.001.
 11. Miyake M, Matsuyama H, Teramukai S, Kinoshita F, Yokota I, Matsumoto H, Shimada K, Kinjyo M, Shimokama T, Okumura K, Yomenori M, Enokida H, Nakagawa M, Nakai Y, Fujimoto K; Nishinohon Uro-oncology Extensive Collaboration group. A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables. *Int J Clin Oncol.* 2020 Mar 30. doi: 10.1007/s10147-020-01654-5. Online ahead of print.
 12. Yoshida T, Kobayashi T, Kawaura T, Miyake M, Ito K, Okuno H, Murota T, Makita N, Kawakita M, Kawa G, Kitawaki T, Fujimoto K, Matsuyama H, Shiina H, Azuma H, Ogawa O, Kinoshita H, Matsuda T. Development and external validation of a preoperative nomogram for predicting pathological locally advanced disease of clinically localized upper urinary tract carcinoma. *Cancer Med.* 2020 Apr 6. doi: 10.1002/cam4.2988. Online ahead of print.
 13. Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, Shinohara N, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H. Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Summary of the Revision. *Int J Urol.* 2020 Jun 21. doi: 10.1111/iju.14281. Online ahead of print.
 14. Matsuyama H, Matsubara N, Kazama H, Seto T, Tsukube S, Suzuki K. Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m²) in patients with

castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study. *BMC Cancer*. 2020 Jul 13;20(1):649. doi: 10.1186/s12885-020-07131-6.

15. Kawai Y, Imada K, Akamatsu S, Zhang F, Seiler R, Hayashi T, Leong J, Beraldi E, Saxena N, Kretschmer A, Oo HZ, Contreras-Sanz A, Matsuyama H, Lin D, Fazli L, Collins CC, Wyatt AW, Black PC, Gleave ME. Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion and Survival of Bladder Cancer. *Mol Cancer Ther*. 2020 Oct;19(10):2210-2220.
16. Yamamoto Y, Yatsuda J, Shimokawa M, Fuji N, Aoki A, Sakano S, Yamamoto M, Suga A, Tei Y, Yoshihiro S, Kitahara S, Nagao K, Takai K, Kamiryo Y, Akao J, Yamaguchi S, Oba K, Shimabukuro T, Matsumoto H, Kamba T, Matsuyama H. Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma. *Int J Clin Oncol*. 2020 Sep 18. doi: 10.1007/s10147-020-01784-w. Online ahead of print. PMID: 32948925.
17. Shiraishi K, Matsuyama H. Outcomes of partial intussusception and endo-to-side vasoepididymostomy in men with epididymal obstructive azoospermia. *Int J Urol*. 2020 Sep 11. doi: 10.1111/iju.14368. Online ahead of print. PMID: 32914440.
18. Shimizu K, Matsumoto H, Hirata H, Ueno K, Samoto M, Mori J, Fujii N, Kawai Y, Inoue R, Yamamoto Y, Yano S, Shimabukuro T, Furutani-Seiki M, Matsuyama H. ARHGAP29 expression may be a novel prognostic factor of cell proliferation and invasion in prostate cancer. *Oncol Rep*. 2020 Dec;44(6):2735-2745.
19. Shiraishi K, Ohmi C, Matsuyama H. Patient-reported outcomes and biochemical alterations during hormonal therapy in men with hypogonadotropic hypogonadism who have finished infertility treatment. *Endocr J*. 2020 Oct 3. doi: 10.1507/endocrj.EJ20-0365. Online ahead of print.
20. Shiraishi K, Oka S, Matsuyama H. Testicular testosterone and estradiol concentrations and aromatase expression in men with nonobstructive azoospermia. *J Clin Endocrinol Metab*. 2020 Nov 25:dga860. doi: 10.1210/clinem/dga860. Online ahead of print.
21. Ito K, Mikami S, Kuroda N, Nagashima Y, Tatsugami K, Masumori N, Kondo T, Takagi T, Nakanishi S, Eto M, Kamba T, Tomita Y, Matsuyama H, Tsushima T, Nakazawa H, Oya M, Kimura G, Shinohara N, Asano T. Difficulty in differential diagnosis for renal cancer with microscopic papillary architecture: overlapped pathological features among papillary renal cell carcinoma (RCC), mucinous tubular and spindle cell carcinoma, and unclassified RCC. Lessons from a Japanese

- multicenter study. *Jpn J Clin Oncol*. 2020 Oct 22;50(11):1313-1320.
22. Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata K, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Mizowaki T, Kamoto T, Kojima T, Kitamura H, Sugimoto M, Nishiyama H, Eto M, Japanese Urological Oncology Group Juog. Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. *Cancer Sci*. 2020 Nov 7. doi: 10.1111/cas.14722. Online ahead of print.
 23. Nakai Y, Takeuchi A, Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Minami K, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Morizane S, Kawasaki Y, Morooka D, Shimazui T, Yamamoto Y, Nakagomi H, Tomida R, Ito YM, Murai S, Kitamura H, Nishiyama H, Shinohara N; Japanese Urological Oncology Group. Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma. *J Geriatr Oncol*. 2020 Dec 30;S1879-4068(20)30534-8.
 24. Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Tamura K, Komiyama M, Goto T, Yokomizo A, Kohei N, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Iwamoto H, Mitsuzuka K, Morooka D, Shimazui T, Yamamoto Y, Ikeshiro S, Nakagomi H, Morita K, Tomida R, Mochizuki T, Inoue T, Kitamura H, Yamada S, Ito YM, Murai S, Nishiyama H, Shinohara N; Japanese Urological Oncology Group. Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma. *Cancer Sci*. 2020 Jul;111(7):2460-2471.
 25. Nishiyama H, Yamamoto Y, Sassa N, Nishimura K, Fujimoto K, Fukasawa S, Yokoyama M, Enokida H, Takahashi K, Tanaka Y, Imai K, Shimamoto T, Perini R, Frenkl T, Bajorin D, Bellmunt J. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. *Int J Clin Oncol*. 2020 Jan;25(1):165-174.

「和文論文」

1. 島袋 智之、大見千英高、白石 晃司、松山豪泰. 血清尿酸値の多変数関連評価法の検討—健常日本人男女における研究—日泌尿会誌. 2020;111(1):22-29.
2. 島袋智之、大見千英高、長光涼子、白石晃司、松山豪泰：前立腺癌患者における Luteinizing Hormone-Releasing Hormone 製剤の局所副反応とその臨床転帰に及ぼす影響。日本泌尿器科学会雑誌 2020; 111(4): 120-129.
3. 松山豪泰.企画にあたって.特集ここが変わった！膀胱がん診療—新ガイドラインを読み解く.臨床泌尿器科. 2020;74(5): 283.
4. 松隈 悠、矢野誠司、松山豪泰、白濱つづり、星井嘉信、河野祐夫. 進行性胚細胞腫瘍と鑑別困難であった鼠径部原発性悪性リンパ腫と肝細胞がんの重複癌の 1 例.西日泌尿. 2020; 82 (3): 368-373.
5. 山本義明、栗林智枝子、小澤翔、佐本征弘、森純一、井上亮、矢野誠司、平田寛、松本洋明、松山豪泰. 転移性尿路上皮癌に対する免疫チェックポイント阻害剤の治療効果について— 放射線治療歴, 病理組織型と治療効果は関連あるか —. 西日本泌尿器科. 2020;82(1): 61-65.